The company has not filed an annual or quarterly report since its Q3 FY2018 10-Q, filed Nov 8, 2018. Its latest SEC filing is a SC 13G/A from Feb 14, 2019.
10-Q for Q3 FY2018, filed Nov 8, 2018
The sections below describe the company as of the FY2017 annual report.
Develops targeted cancer drugs and companion imaging agents, including radioligand therapies and adaptor-controlled immune-cell treatments, for people with cancer.
10-K for FY2017, filed Feb 27, 2018We are a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. We use drug conjugation…View ↗
CAR T-Cell Therapy. We are also developing a unique therapeutic approach that involves the re-targeting of potent immune cells, called…View ↗
Radioligand therapy. We have expanded our technology platform to RLTs. In this modality, a high affinity cancer targeting ligand is…View ↗
Past revenue came from upfront license payments and collaboration agreements. Upfront amounts could be spread across research work, development milestones were tied to reaching milestones, and sales milestones and royalties were tied to sales; the company says those agreements have ended, leaving revenue from an earlier NMP upfront payment.
10-K for FY2017, filed Feb 27, 2018The Company recognizes revenues from license and collaboration agreements when persuasive evidence of an arrangement exists, delivery has…View ↗
Upfront payments for licensing the Company’s intellectual property are evaluated to determine if the licensee can obtain stand-alone value…View ↗
Milestone payments under collaborative arrangements are triggered either by the results of the Company’s research and development efforts…View ↗
To date, we have not derived any revenue from the sales of our products. Our operations to date have been limited to acquiring, developing…View ↗
$70K
10-K for FY2016, filed Mar 13, 2017
$70K ↗
Licensees and research collaborators paid under agreements for intellectual-property rights and research services; the company says all of its collaboration agreements have ended.
10-K for FY2017, filed Feb 27, 2018
No. It lost $43.9M in FY2016.
10-K for FY2016, filed Mar 13, 2017
10-Q for Q3 FY2018, filed Nov 8, 2018
−$12.6MView ↗
8-K, filed Dec 21, 2018
Pursuant to the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each issued and outstanding share of Endocyte…View ↗
Shrank. Revenue fell 100% in 4 years, from $34.7M in FY2012 to $70K in FY2016, about 79% a year.
A narrower treatment focus
The older portfolio covered folate-targeted drug conjugates and inflammatory diseases; the latest report centers on a PSMA-targeted radioligand therapy and a proof-of-concept immune-cell program, while seeking partners for other programs.
10-K for FY2014, filed Mar 13, 2015 10-K for FY2017, filed Feb 27, 2018Radioligand therapy. We have expanded our technology platform to RLTs. In this modality, a high affinity cancer targeting ligand is…View ↗
CAR T-Cell Therapy. We are also developing a unique therapeutic approach that involves the re-targeting of potent immune cells, called…View ↗
Since our inception, we have been focused on the development of our targeting ligand conjugate technology candidates. In June 2017, we…View ↗
On September 29, 2017, we entered into the License Agreement with ABX, and on October 2, 2017, we announced our plan to primarily focus our…View ↗
Competes with Adaptimmune Therapeutics, Affimed, AstraZeneca, Atara Biotherapeutics, Atridia, Autolus, Bayer, Bellicum Pharmaceuticals, BioNTech, Bluebird Bio, Cancer Targeted Technology, Celgene, Cellectis, Celyad, Editas Medicine, ESSA Pharma, Gilead Sciences, GlaxoSmithKline, Immatics Biotechnologies, and Immunocore
10-K for FY2017, filed Feb 27, 2018Many of our competitors have significantly greater financial, manufacturing, marketing and drug development resources than we do. Large…View ↗
Loading...
